Detection and monitoring of ovarian cancer

Su, Zengliu; Graybill, Whitney; Zhu, Yusheng

doi:10.1016/j.cca.2012.10.058

Cited by 86 publications

(58 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Largely asymptomatic, ≥70% of patients with ovarian cancer have reached an advanced stage of the disease by the time of initial diagnosis, and the overall five-year survival rate for these patients is <30% (3). The current regimen of chemotherapy for ovarian cancer consists of a taxane and platinum based therapy (4).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparative secretome of ovarian serous carcinoma: Gelsolin in the spotlight

et al. 2017

View full text Add to dashboard Cite

Abstract. Ovarian cancer is one of the most common types of reproductive cancer, and has the highest mortality rate amongst gynecological cancer subtypes. The majority of ovarian cancers are diagnosed at an advanced stage, resulting in a five-year survival rate of ~30%. Early diagnosis of ovarian cancer has improved the five-year survival rate to ≥90%, thus the current imperative requirement is to identify biomarkers that would allow the early detection, diagnosis and monitoring of the progression of the disease, or of novel targets for therapy. In the present study, secreted proteins from purified ovarian control, benign and cancer cells were investigated by mass spectrometry, in order to identify novel specific markers that are easy to quantify in patients sera. A total of nine proteins revealed significant differential secretion from control and benign cells, in comparison with ovarian cancer cells. The mRNA expression levels of three of these proteins (Dickkopf protein 3, heat shock protein 10 kDa and gelsolin) were subsequently evaluated by reverse transcription-quantitative polymerase chain reaction. Combined with the protein level in serum, the present study identified that gelsolin may be a useful marker of ovarian cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

“…However, following a short remission period (usually 6-22 months), recurrence occurs in almost all patients (3). The lack of effective diagnostic and prognostic tools for ovarian cancer renders this particular type of cancer challenging to manage, and the majority of patients develop chemotherapy resistant tumors and relapse (3).…”

Section: Introductionmentioning

confidence: 99%

Comparative secretome of ovarian serous carcinoma: Gelsolin in the spotlight

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Among a wide spectrum of serum biomarkers proposed to aid in the diagnosis of women presenting with a suspicious pelvic mass, human epididymis protein 4 (HE4), has been introduced as a novel biomarker for ovarian cancer diagnosis (Hellström et al, 2003;Su et al, 2013). HE4 was found to offer a better diagnostic performance than CA125 for distinguishing between benign and malignant pelvic masses (Holcomb et al, 2011;Zheng and Gao, 2012;Chung et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses

Fawzy

Mohamed²,

Ali³

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…The survival rate is related Hakkı Sencer Simsek 1 , Aytekin Tokmak 1 *, Emre Ozgu 1 , Melike Doganay 1 , Nuri Danısman 1 , Salim Erkaya 1 , Tayfun Gungor 2 to the stage of the disease at the diagnosis (Ashrafgangooei et al, 2011). In patients diagnosed with advanced stage III-IV ovarian cancer, the 5-year survival rate is about 30%, whereas in those diagnosed at an early stage the 5-year survival rate is about 90% (Su et al, 2013). Therefore it seems worthwhile to detect ovarian cancer at an early stage (Mathevet et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Role of a Risk of Malignancy Index in Clinical Approaches to Adnexal Masses

Simsek¹,

Tokmak²,

Özgü³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Objective: The aim of this study was to evaluate predictive role of risk of malignancy index in discriminating between benign and malignant adnexal masses preoperatively. Methods: This retrospective study was conducted with a total of 569 patients with adnexal masses/ovarian cysts managed surgically at our clinic between January 2006 and January 2012. Obtained data from patient files were age, gravidity, parity, menopause status, ultrasound findings and CA125 levels. For all patients ultrasound scans were performed. For the assessment of risk of malignancy index (RMI) Jacobs' model was used. Histopathologic results of all patients were recorded postoperatively. Malignancy status of the surgically removed adnexal mass was the gold standard. Results: Of the total masses, 245 (43.1%) were malignant, 316 (55.5%) were benign and 8 (1.4%) were borderline. The mean age of benign cases was lower than malign cases (35.2±10.9 versus 50.8±13.4, p<0.001). Four hundred and five of them (71.2%) were in premenopausal period. Malignant tumors were more frequent in postmenopausal women (81% versus 29%, p<0.001). All ultrasound parameters of RMI were statistically significantly favorable for malignant masses. In our study ROC curve analysis for RMI provided maximum Youden index at level of 163.85. When we based on cutoff level for RMI as 163.85 sensitivity, specificity , PPV, NPV was calculated 74.7%, 96.2%, 94% and 82.6%, respectively. Conclusions: RMI was found to be a significant marker in preoperative evaluation and management of patients with an adnexal mass, and was useful for referring patients to tertiary care centers. Although utilization of RMI provides increased diagnostic accuracy in preoperative evaluation of patient with an adnexal mass, new diagnostic tools with higher sensitivity and specificity are needed to discriminate ovarian cancer from benign masses.

show abstract

Detection and monitoring of ovarian cancer

Cited by 86 publications

References 46 publications

Comparative secretome of ovarian serous carcinoma: Gelsolin in the spotlight

Comparative secretome of ovarian serous carcinoma: Gelsolin in the spotlight

Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses

Role of a Risk of Malignancy Index in Clinical Approaches to Adnexal Masses

Contact Info

Product

Resources

About